Vivos Therapeutics (VVOS) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for Vivos Therapeutics (VVOS) over the last 4 years, with Q3 2025 value amounting to -$0.49.
- Vivos Therapeutics' EPS (Weighted Average and Diluted) fell 2250.0% to -$0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.77, marking a year-over-year increase of 6883.8%. This contributed to the annual value of -$2.23 for FY2024, which is 7998.27% up from last year.
- According to the latest figures from Q3 2025, Vivos Therapeutics' EPS (Weighted Average and Diluted) is -$0.49, which was down 2250.0% from -$0.55 recorded in Q2 2025.
- Vivos Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.33 for Q2 2022, and its period low was -$6.61 during Q4 2022.
- For the 4-year period, Vivos Therapeutics' EPS (Weighted Average and Diluted) averaged around -$2.08, with its median value being -$1.12 (2024).
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 130000.0% in 2023, then skyrocketed by 8701.3% in 2024.
- Vivos Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$6.61 in 2022, then soared by 53.89% to -$3.05 in 2023, then surged by 81.16% to -$0.57 in 2024, then increased by 14.74% to -$0.49 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.49 for Q3 2025, versus -$0.55 for Q2 2025 and -$0.45 for Q1 2025.